Poolbeg Pharma PLC Notice of Results (9441C)
February 28 2022 - 1:01AM
UK Regulatory
TIDMPOLB
RNS Number : 9441C
Poolbeg Pharma PLC
28 February 2022
Poolbeg Pharma plc
Notice of Results
28 February 2022 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the
'Company') a clinical stage infectious disease pharmaceutical
company with a unique capital light clinical model , will announce
its results for the period ended 31 December 2021 on Thursday 3
March 2022.
The Company will be hosting an online presentation for investors
on the same day, at 6:00pm GMT on the Investor Meet Company
platform.
The presentation is open to all existing and potential
shareholders. Investors can register to attend here:
www.investormeetcompany.com/poolbeg-pharma-plc/register-investor
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
finnCap Ltd (Nominated Adviser & Joint
Broker)
Geoff Nash, James Thompson, Charlie
Beeson,
Richard Chambers, Sunila de Silva (ECM) +44 (0) 207 220 0500
Arden Partners PLC (Joint Broker)
John Lewellyn-Lloyd, Louisa Waddell +44 (0) 207 614 5900
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Instinctif Partners +44 (0) 20 7457 2020
Melanie Toyne Sewell, Rozi Morris, Tim poolbeg@instinctif.com
Field
About Poolbeg Pharma
Poolbeg Pharma (AIM:POLB) is a clinical stage infectious disease
pharmaceutical company with a capital light clinical model which is
developing multiple products faster and more cost effectively than
the conventional biotech model. The Company, headquartered in
London, is led by a team with a track record of creation and
delivery of shareholder value and aspires to become a "one-stop
shop" for Big Pharma seeking mid-stage products to licence or
acquire.
The Company is targeting the growing infectious disease market
which has become one of the fastest growing pharma markets and is
expected to exceed $250bn by 2025.
Poolbeg has access to extensive knowledge, experience, and
clinical data from over 20 years of human challenge trials through
Open Orphan plc , an industry leading infectious disease and human
challenge trials business. The Company is using these insights to
acquire new assets as well as reposition clinical stage products,
reducing spend and risk.
The Company continues to rapidly expand its portfolio of assets
which currently includes POLB 001, a repositioned small molecule
immunomodulator for severe influenza. POLB 002, a first-in-class,
intranasally administered, RNA-based immunotherapy for respiratory
virus infections and POLB 003, an intramuscular Melioidosis
vaccine. The Company is also developing an oral vaccine delivery
platform and as well as progressing its AI powered drug discovery
program to identify pathways and drug candidates using its disease
progression data.
For more information, visit www.PoolbegPharma.com or follow us
@PoolbegPharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBDLLLLLLXBBX
(END) Dow Jones Newswires
February 28, 2022 02:01 ET (07:01 GMT)
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jul 2023 to Jul 2024